NEW YORK (GenomeWeb News) – Shares of DeCode Genetics climbed more than 40 percent today following an announcement that the company had discovered two SNPs associated with the risk of basal cell carcinoma, the most common cancer among people of European ancestry.
 
The boost in DeCode’s shares, which opened at $.36 today and were priced at $.54 in mid-afternoon trading, outpaced a broad rally in the capital markets following a massive sell-off in recent weeks.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

In Nature this week: shared genetic architecture for asthma and allergic diseases, and more.

A survey of Canadians finds them to be divided on genetically modified food, the Ottawa Citizen reports.

Science speaks with the University of Michigan's Jedidiah Carlson, who has tracked population genetic discussions at white nationalist sites.

Gene therapies could qualify for a faster US Food and Drug Administration approval process, according to Stat News.